Girish Kumar SRIVASTAVA

Dr. Girish Kumar SRIVASTAVA

Universidad de Valladolid, Valladolid, Castille-Leon, Spain
orcid
Investigator UVa & Editor in chief Allbiosolution

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
MAMaria L. Alonso-Alonso
Maria L. Alonso-Alonso
IFIvan Fernandez-Bueno
Ivan Fernandez-Bueno
MGMaria T. Garcia-Gutierrez
Maria T. Garcia-Gutierrez
FRFernando Rull
Fernando Rull
JPj Pastor
j Pastor
A series of recent acute blindness cases following non–complicated retinal detachment surgery caused the release of several health alerts in Spain. The blindness was attributed to certain lots of perfluoro-octane (PFO; a volatile and transient medical device). Similar cases have been reported in other countries. This has raised questions regarding the validity of cytotoxicity test methods currently used to certify the safety of PFO lots. The tests were performed according to the International Organization for Standardization (ISO) norms, using the extract dilution method or the indirect contact method as applied to L929 cells, a line derived from mouse fibroblasts. The limitations of those methods have been resolved in this study by proposing a new cytotoxicity test method for volatile substances. The new method requires direct contact of the tested substance with cells that are similar to those exposed to the substance in the clinical setting. This approach includes a few new technical steps that are crucial for detecting cytotoxicity. Our new method detected toxic PFO lots that corresponded to the lots producing clinical blindness, which previous methods failed to detect. The study suggests applying this new method to avoid occurrence of such cases of blindness.

3 October 2010 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
CRCarmen Ruiz-Ruiz
Carmen Ruiz-Ruiz
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
DCDiana Carranza
Diana Carranza
JMJuan A. Mata
Juan A. Mata
Inmaculada LlamasInmaculada Llamas
Inmaculada Llamas
IMIgnacio J. Molina
Ignacio J. Molina

3 May 2024 in Polymers
Verified
Journal Article
Open access
PDF file
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
SRSofía Martínez Rodríguez
Sofía Martínez Rodríguez
Nur Izzah Md FadilahNur Izzah Md Fadilah
Nur Izzah Md Fadilah
DHDaniel Looi Qi Hao
Daniel Looi Qi Hao
GMGavin Markey
Gavin Markey
FPFivos Panetsos
Fivos Panetsos
Wounds are breaks in the continuity of the skin and underlying tissues, resulting from external causes such as cuts, blows, impacts, or surgical interventions. Countless individuals suffer minor to severe injuries, with unfortunate cases even leading to death. In today’s scenario, several commercial products are available to facilitate the healing process of wounds, although chronic wounds still present more challenges than acute wounds. Nevertheless, the huge demand for wound-care products within the healthcare sector has given rise to a rapidly growing market, fostering continuous research and development endeavors for innovative wound-healing solutions. Today, there are many commercially available products including those based on natural biopolymers, stem cells, and microRNAs that promote healing from wounds. This article explores the recent breakthroughs in wound-healing products that harness the potential of natural biopolymers, stem cells, and microRNAs. A comprehensive exploration is undertaken, covering not only commercially available products but also those still in the research phase. Additionally, we provide a thorough examination of the opportunities, obstacles, and regulatory considerations influencing the potential commercialization of wound-healing products across the diverse markets of Europe, America, and Asia.

1 December 2011 in Experimental Eye Research
Verified
Journal Article
Closed access
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
RTROBERTO REINOSO TAPIA
ROBERTO REINOSO TAPIA
ASAmar K. Singh
Amar K. Singh
IFIvan Fernandez-Bueno
Ivan Fernandez-Bueno
DHDenise Hileeto
Denise Hileeto
JPj Pastor
j Pastor

3 March 2005 in Gene Therapy
Verified
Journal Article
Open access
PDF file
Francisco MartinFrancisco Martin
Francisco Martin
MTM Ga Toscano
M Ga Toscano
MBM Blundell
M Blundell
CFCecilia Frecha
Cecilia Frecha
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
IMI J Molina
I J Molina
The development of vectors that express a therapeutic transgene efficiently and specifically in hematopoietic cells (HCs) is an important goal for gene therapy of hematological disorders. In order to achieve this, we used a 500 bp fragment from the proximal WASP gene promoter to drive the expression of the WASP cDNA in the context of a self-inactivating lentiviral vector. Single-round transduction of WASp-deficient herpesvirus saimiri (HVS)-immortalized cells as well as primary allospecific T cells from Wiskott–Aldrich syndrome (WAS) patients with this vector (WW) resulted in expression levels similar to those of control cells. Non-HCs were transduced with similar efficiency, but the levels of WASp were 135–350 times lower than those achieved in HCs. Additionally, transduction of WASp-deficient cells with WW conferred a selective growth advantage in vitro. Therefore, lentiviral vectors incorporating proximal promoter sequences from the WASP gene confer hematopoietic-specific, and physiological protein expression.

25 March 2011 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
Laura MartinmLaura Martinm
Laura Martinm
ASAmar K. Singh
Amar K. Singh
IFIvan Fernandez-Bueno
Ivan Fernandez-Bueno
MGManuel Garrosa
Manuel Garrosa
JPj Pastor
j Pastor